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Abstract
Purpose Patients with a substance use disorder (SUD),
admitted for detoxification, often suffer from a poor quality
of life (QoL). We set out to monitor QoL, together with
substance use, in a departure from the usual norm of
measuring substance use alone as a treatment outcome.
Literature searches revealed scant knowledge of how QoL
is influenced. With this in mind, we aimed to investigate
whether total abstinence, prior to follow-up, could influ-
ence QoL.
Methods We studied a prospective cohort of 140 patients
admitted for inpatient detoxification treatment at Sørlandet
Hospital (Norway), from September 2008 to August 2010.
QoL was measured by a generic five-item questionnaire,
the QoL-5. The extremes of this scale ranged from the
worst possible rating of 0.1 to 0.9, as the best. A norm for
the general population was benchmarked at 0.69. Change
in QoL was calculated by subtracting baseline QoL from
that achieved at the 6-month follow-up interview; linear
regression modeling was used to study the influence of
individual QoL predictors.
Results The mean QoL at baseline was 0.46, 39 % below
that of the general reference population. By applying the
clinical interpretation of the scale, we found a modest
overall mean improvement in QoL at follow-up (0.11
points); the greatest increases were seen for patients with
the lowest baseline QoL scores. Abstinence prior to follow-
up correlated with improved QoL, while living alone and
psychological distress were negative influences.
Conclusions For patients with a SUD, clinicians should
emphasize that abstinence may help to improve their QoL.
Keywords Substance use disorders  Treatment
outcome  Norway
Background
Substance use disorders (SUDs) cause a spectrum of health
problems, one of which is to increase the number of years
lived with a disability [1]. Research in this area indicates
that a SUD can affect well-being and function across a
number of areas in life, and may lead to a considerable
deterioration of physical health [2, 3], and social func-
tioning [4]. Psychiatric disorders and SUDs are also com-
mon comorbidities; thus, impaired psychological health
and reduced well-being often co-exist [5]. Physical health
and mental health are the two integral quality of life (QoL)
components [6]. For SUD researchers, their evaluation
represents a qualitative improvement in outcome mea-
surement, beyond the established practice of focusing
solely on substance use [7]. The addiction research field
has, to some degree, responded to the need to investigate
QoL more methodically, and the number of articles that
derive correlates between QoL and substance use has
increased in the last decade [3, 8, 9].
The goal of SUD treatment is to initiate rehabilitation,
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use and to help patients to become engaged with their own
long-term recovery [10, 11]. An overarching aim is there-
fore to improve QoL. If living without substance use is to
be the goal for the SUD patient, then this outcome must be
associated with improved well-being, for at least some
facets of life. Otherwise, this aim will simply not be per-
ceived as ‘‘worth’’ fighting for. Consequently, patients may
lose motivation and interest in their rehabilitative process
[12].
Detoxification (detox) treatment is considered to be one
way to initiate the recovery process. Ideally, patients
should transition post-detox, to more extensive and longer
term SUD treatment. The reality though is that many
patients will only experience detox [13]. As a stand-alone
intervention, detox may fail to prevent the patient from
reverting back to a state of continued substance use [13].
The QoL of patients admitted to detox has, to some
degree, been assessed, but many studies only utilize cross-
sectional designs, survey patients only at admission and
discharge [14–16], or typically have short follow-up peri-
ods, e.g., up to 3 months [17]. Thus, there is still a lack of
prospective studies that have examined QoL changes at
lengthier time frames after detox. Encouraging exceptions
exist though. Picci et al. [18] examined variations in QoL,
up to 12 months following detox, to evaluate the predictive
value of QoL for relapse and the severity of alcohol use.
They found that baseline QoL was not predictive of either
relapse or alcohol use severity at follow-up. A secondary
finding was that a significant QoL improvement was seen
among patients who had achieved abstinence, with QoL
scores among relapsed patients unchanged.
This finding epitomizes a typical dispute in this field:
whether abstinence is a necessary precondition for QoL
improvement or whether any reduction in substance use
will, as a byproduct, improve QoL [7, 19]. As previously
mentioned, there is evidence to show that QoL improves
with abstinence and deteriorates with relapse [18, 20], but
the findings are mixed. For example, a recent Norwegian
study found no association between abstinence and QoL
among SUD patients at their six-month post-treatment
follow-up [21]. In a second, US-based study, three months
of outpatient SUD treatment also failed to reveal any cor-
relates between QoL and changes in alcohol and drug
consumption [22]. Similarly, in a series of shorter detox
studies, Foster et al. [17, 23, 24] reported an improvement
in QoL for only some alcohol-dependent individuals when
they changed their pattern of alcohol usage. The question
has also been raised as to the definition of the rather broad
term ‘‘recovery’’. Is abstinence a defining element, or is it
just one of many strategies for achieving recovery [10, 25].
The present study is among the few studies focusing on
QoL after detox treatment that have a longer follow-up
than 3 months and have the relationship between QoL and
abstinence as its main focus.
Purpose
The aim of this study was to (1) examine QoL changes
from baseline to the six-month follow-up interview (post-
discharge) and (2) determine whether abstinence in the
month preceding the follow-up interview predicted out-
come (QoL), while controlling for other potential variables.
We hypothesized that being abstinent during the 30 days




This study reports pre- and post-treatment QoL status of a
cohort of patients recruited to a controlled trial on a
detoxification ward at the Addiction Unit, Sørlandet
Hospital, in Kristiansand, Norway, between September
2008 and August 2010. Detoxification treatment in Norway
typically engages three types of patient group; patients
detoxed before their admittance into longer term, inpatient
treatment; patients initiating opioid maintenance treatment
(OMT); and patients who receive a detox and are subse-
quently discharged. The latter group, those discharged with
no immediate plans for further inpatient or OMT treatment,
was approached to enroll in this study. Their eligibility was
based on the central tenet of this study, to test how patients,
post-discharge, could be motivated to seek their own sup-
port in community-based, addiction-related, mutual-help
groups (MHGs) [11]. Exclusion criteria for our study
included severe psychiatric disorders or cognitive impair-
ment. Of 156 eligible patients, 16 declined to participate,
leaving a final cohort of 140 patients, representing 89 % of
the original eligible respondents (Table 1). We have pre-
viously published a detailed description of our patient
cohort, and their treatment setting, in the context of a
separate study on motivational intervention [11]. The
Regional Ethics Committee of the South-East Health
Region, Norway, approved the study.
Measures and procedures
To avoid any influence of withdrawal symptoms on QoL
baseline scores, patients were neither approached nor
recruited to this study until they had passed the acute
detoxification phase. Therefore, patients were first
approached to participate in this study at a mean timepoint
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of 4.5 days after their admission. After providing informed
consent, participants were assessed with a QoL measure
(see below) and completed the semi-structured EuropASI
interview to collect data on patient demographics, back-
ground, treatment history, and substance use [26]. The time
frame for the EuropASI is the 30 days preceding the
interview, and data on drug and alcohol use in the 30 days
prior to admission yielded composite scores to indicate
severity of substance abuse [27]. Scores ranged from 0 (no
problem) to 1 (a severe problem). As the ward admitted
patients with both alcohol and drug dependence, we also
included an overall substance use severity measure; the
Survey of Readiness for AA Participation (SYRAAP)
severity subscale [28]. The five questions of the scale, e.g.,
‘‘My substance use has hurt some other people’’ and
‘‘Using substances has interfered with my ability to deal
with everyday problems,’’ were rated on a five-point Lik-
ert-type response format, from scale 1 (strongly disagree)
to scale 5 (strongly agree). A mean score was computed; a
higher score meant higher severity. A score C4 on the
SYRAAP scale is considered to reflect a serious substance
use problem [29]. The Mini International Neuropsychiatric
Interview (MINI), version 5.0, was used to confirm the
SUD diagnosis [27]. To assess mental health, we used
Symptom Check List-10 (SCL-10), a measure of psycho-
logical distress (scale 1–4 [30]). A mean score (global
score index) was computed; the higher the score, the
greater the distress. A score of C1.85 using SCL-10 is
considered to be a pathological score [29, 30].
At the six-month follow-up interview, 113 patients
(81 %) were successfully contacted and re-assessed using
Europ-ASI and the QoL survey described below. Those
lost to follow-up were younger (35 vs. 43 years; t = 2.6,
degrees of freedom = 138; p\ 0.01), but otherwise had
no defining characteristics. The mean QoL scores at
baseline for those lost to follow-up were comparable to
those who engaged with the study.
Outcome
Quality of life was measured at baseline and at follow-up
using the QoL-5 test, a short, generic QoL instrument. This
survey does not focus on any disease-related deficits, but
instead assesses the patient’s satisfaction with life in gen-
eral [31]. QoL-5 consists of five subjective statements: two
questions are about health, physical, and mental; two
Table 1 Characteristics of
study respondents (N = 140)
Characteristic N (%) or mean (SD)
Age, years 41 (14)
Female 45 (32)
Proportion native Norwegians or European origin 134 (96)
Education, years 11.2 (2.3)
Relationship, proportion living in relationship 74 (53)
Main diagnosis (ICD-10)
(1) Alcohol dependence (N = 48) or harmful alcohol use (N = 6) 54 (39)
(2) Both alcohol and drug dependence 26 (19)
(3) Drug dependence 60 (43)
Severity variables
Earlier SUD treatment (prior to current detoxification) 108 (77)
Years of problematic usea of the major drugs of abuse 11.4 (9.0)
Alcohol composite score (EuropASI)b 0.43 (0.36)
Drug composite score (EuropASI)b 0.25 (0.20)
Self-rated substance use severityc 4.2 (0.7)
Injection use in the last 6 months 40 (29)
Psychological distressd 2.4 (0.7)
Quality of lifee 0.46 (0.15)
Days on the ward 11 (5)
a Problematic use, as defined in EuropASI, was the consumption of 5 or more standard drinks at least 3
times weekly, or binge drinking on 2 consecutive days to a level that affected daily functioning. For drug
use, only frequency was needed; 3 times weekly or 2 consecutive days
b EuropASI composite score, scale 0–1
c SYRAAP, severity score of the substance use, scale 1–5
d SCL-10, global score index, scale 1–4
e QoL-5, scale 0.1–0.9
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questions address the quality of significant relationships
(partner and friends); and one question addresses the
existential self, i.e., the relationship with oneself.
Responses were scored on a five-step ordinal scale from 1
to 5. A score of 1 is very good, and 5, very poor. The raw
scores were then transposed, and inverted as a decimal
scale ranging from 0.1 to 0.9; 0.9 was now the best score,
and 0.1, the worst [32]. Mean scores for health, relation-
ships, and the existential self, were calculated, and a total
QoL score, derived. For patients without a partner, the
relationship sub-score was based on one question only.
Normative data from a previous survey of the general
population showed a mean QoL score of 0.69 [31, personal
communication]. This was used as our reference population
QoL. The cutoff score for a markedly reduced QoL was
suggested to be*0.15 below that of the general population
(B0.55). Scores lower than 0.40 were considered to be
severely reduced [21]. Changes in QoL were computed by
subtracting the QoL determined at admission from the QoL
obtained at follow-up, hereafter called the ‘‘QoL score
change’’. A QoL score increase from baseline to follow-up
of 0.2 (a one-point increase on the raw score scale, e.g.,
from ‘‘good’’ to ‘‘very good’’) or higher was denoted as
substantial and indicated a clinically important improve-
ment. Other QoL changes were considered moderate (C0.1
score), small (C0.05 score), or very small (\0.05) [31, 32].
The internal consistency of the scale was good; the Cron-
bach’s alpha coefficient was 0.75 and 0.81 for the QoL-5 at
baseline and follow-up, respectively [33].
Factors associated with QoL
To examine determinants of QoL at follow-up, the socio-
demographic variables of gender, age, and whether patients
were in a relationship at baseline were included as potential
predictors. Of the clinical variables collected at baseline,
we included patients’ self-rated severity of substance use
using the SYRAAP severity score and their perceived
mental health status using the SCL-10 assessment. The
reliability of the scales was good; the Cronbach’s alpha
coefficient was 0.75 and 0.91 for the SYRAAP and SCL-
10, respectively. We also took into account two additional
predictors that could influence outcome: inpatient treat-
ment (scored in days) and MHG support (scored as number
of MHG meetings attended) during the six-month follow-
up period. Substance use at follow-up was assessed with
the EuropASI. Substance use status and whether patients
were abstinent or not was determined according to self-
reported alcohol and drug use for the 30 days preceding the
follow-up interview, i.e., the abstinent group had no alco-
hol or drug use during this period.
Statistical analyses
Descriptive statistics were used to elaborate baseline
characteristics. To descriptively show the 6-month change
in relation to patients’ QoL status, QoL changes were
grouped according to the baseline QoL status. These were
either severely reduced (\0.40), markedly reduced
(0.40–0.55), or close to normal QoL ([0.55). Two different
t-tests were used; paired sample t-test was used to examine
the 6-month change in substance use and QoL, and the
Student’s t-test was used to explore between group dif-
ferences on the QoL change score and QoL score at follow-
up.
Linear regression with simultaneous entry of variables
(the ‘‘enter’’ method) was used to examine predictors of
QoL at follow-up. Baseline QoL was included in the
analysis to control for a possible ceiling effect, i.e., those
who already had a near-to-normal QoL at baseline were not
expected to manifest any marked improvement. Results are
presented as unstandardized beta coefficients with 95 %
confidence interval (CI). The R-square (R2) value was used
to assess the proportion of variability in the dataset.
Analyses of variables were considered to be statistically
significant at a p value of\0.05; all analyses were per-
formed using IBM SPSS Statistics version 21.
Results
The sample was a mixed population with either an alcohol
and/or a drug use disorder. Patients had in excess of
11 years of problematic use of their major substance of
abuse; 77 % had received prior specialized SUD treatment,
and 29 % had used an injected drug in the 6 months prior
to admission (Table 1). The mean QoL for our cohort at
baseline was 0.46, which is 0.23 below that of the general
population, representing a relative drop of 39 % when
taking the lowest extreme of the scale into account. Thirty-
seven percent of our patients had a markedly reduced QoL
score (0.40–0.55), and a further 32 % had a severely
reduced QoL (\0.40).
Although the patients were not intended to be directly
transferred to further SUD treatment upon discharge, those
who were reached at follow-up had received a mean of
18 days (median 0, range 0–180) of inpatient treatment
during the 6-month follow-up period. They had also
attended a mean of 12 MHG meetings (median 1, range
0–97). Patients reported a significant reduction in substance
use; the alcohol composite score using the EuropASI test
decreased from 0.45 to 0.21 (-0.24, 95 % CI for the dif-
ference = -0.18/-0.31, p\ 0.001), and the drug com-
posite score decreased from 0.25 to 0.10 (-0.14, 95 % CI
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for the difference = -0.11/-0.17, p\ 0.001). Almost half
of the sample, 52 patients (46 %), reported total abstinence
from all substances for the 30 days preceding the follow-up
interview.
In terms of QoL change, for the sample as a whole, there
was only a modest improvement (0.11, 95 % CI 0.08–0.15,
p\ 0.001, paired sample t-test), contributed to in the main
by more pronounced progress among those with the lowest
baseline scores (Fig. 1 ). With reference to the main focus
of this study, whether abstinence status was associated with
differences in QoL, those who were abstinent before fol-
low-up recorded substantial, and clinically relevant,
improvements (0.19, 95 % CI 0.13–0.25). In comparison,
those reporting continued substance use achieved small
improvements in QoL (0.05, 95 % CI 0.01–0.08). Thus, the
unadjusted mean difference between the groups was 0.14
and was found to be statistically significant (95 % CI
0.08–0.21, p\ 0.001). Additionally, the two groups were
assessed by a 6-month, post-treatment survey, for their
mean scores for each individual QoL item. Collectively,
abstinence prior to follow-up resulted in improved scores
for psychological health, existential QoL, and overall QoL-
5 (Fig. 2).
Considering abstinence as a predictor for QoL in a mul-
tiple linear model, and when controlling for demographic
and clinical variables, abstinence was still found to be a
significant predictor (b 0.12, 95 % CI 0.06–0.18, Table 2).
The unadjusted significance of abstinence on QoL was
slightly greater (0.14). Other significant predictors were
living alone (b -0.08, 95 % CI -0.14/-0.02) and psycho-
logical distress (b-0.08, 95 %CI-0.13/-0.02); these both
influencedQoL negatively. Our analysis was adjusted for the
QoL-5 score at baseline, which in itself was not significant.
Neither inpatient treatment, nor MHG attendance during
follow-up, contributed to any variance for our dependent
variable. In terms of data fit, our model explained 33 % (R2)
of the variance found for QoL.
Discussion
The majority of patients with SUDs undergoing detoxifi-
cation had markedly impaired QoL at treatment inclusion.
At the six-month follow-up, those who were abstinent had
a substantial improvement in their QoL, while those still
using substances manifested a modest improvement in
QoL. Multivariate analysis corroborated these findings,
with abstinence identified as a positive predictor of QoL,
while living alone and psychological distress were negative
influences.
The markedly reduced QoL of SUD patients at admis-
sion confirms findings in previous studies that patients with
SUDs experience low levels of QoL compared with the
general population and compared to those with other
chronic health conditions [34]. This has also been seen in
previous samples of patients admitted for detox [15, 35].
For example, compared to the normative score for the
general population, a*22 % reduction in score was found
using the SF-36 survey, for patients on their admission to
detoxification in a French study [15]. The mean QoL score
in the present study was even lower, 39 % lower than that
of the reference population. We should, however, note one
caveat for this comparison that different measures were
used to assess QoL. Therefore, the French study [15] and
the current study are not directly comparable.
Fig. 1 QoL changes from baseline to follow-up based on QoL status
at baseline (N = 113). Green line mean score of a general reference
population. Red line mean change of patients with near-to-normal
QoL at baseline ([0.55). Yellow line mean change of patients with
markedly reduced QoL at baseline (0.40–0.55). Blue line mean























Fig. 2 Comparison of QoL scores of patients that were abstinent or
relapsed at follow-up (N = 113). Blue line patients abstinent last
30 days before follow-up. Red line patients relapsed in the last
30 days before follow-up. *p value for the difference (Student’s t-
test)\ 0.05
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Considering QoL change, there appeared to be a ceiling
effect in that those patients with a near-normal QoL at
baseline had unchanged QoL at follow-up; any substantial
improvement was confined to those who were initially
worse off. This has previously been shown in a study that
measured QoL during a short residential stay of 3 weeks
[15]. Our study, with its 6-month follow-up interview,
showed that a higher QoL at baseline was not predictive of
a superior QoL at the 6-month after discharge. This is
somewhat contrary to findings in the large New European
Alcoholism Treatment study (NEAT), in which the patients
with an initially poor QoL had a worse prognosis [35]
However, although those with markedly reduced and
severely reduced QoL at baseline achieved the most pro-
nounced progress in the current study, they still failed to
attain the QoL scores of those who had a near-normal QoL
score at baseline.
As hypothesized, abstinence was associated with a better
QoL at follow-up, similar to the findings of Picci et al. [18].
Unlike that study, however, our non-abstinent participants
also reported some improvement in their QoL, but this was
considered to be a minor influence when evaluated clini-
cally. Thus, our study indicates that achieving abstinence is
an important factor in improving QoL. Both abstinent and
non-abstinent patients rated the quality of their relation-
ships to friends and partners at a similar level, but the
groups differed significantly in their psychological health,
and relationship to self, assessments. Broadly put, the
improved QoL of those who were abstinent seemed to be
brought about by improved psychological health and a
positive change in their relationship to self. This indicates
that individual components of QoL change differently with
time in relation to recovery status and that abstinence
predominantly influenced these two QoL components.
Thus, with abstinence, there are parallel gains in emotional
and ontological health.
Living alone, i.e., living without support from a close
partner resulted in a deterioration in QoL. Patients with a
SUD often suffer from broken relationships or the family
and/or social network may be worn out by trying to help or
mitigate the consequences of the condition [36, 37]. Hence,
in the case of a patient with a SUD, living alone may not
necessarily be a choice. The upshot is that positive familial
restraining influences may no longer be present. There may
also be a lack of motivational support to promote self-help
and agency in the patient. Our data agree with an earlier
study among alcoholics undergoing rehabilitation [38]. In
that case, the authors found that the perception of being
lonely and feelings of loneliness were robust predictors of
poor QoL and prognosis.
A previous meta-analysis found that the most powerful
predictor of lower levels of QoL at admission to SUD
treatment was the perceived severity of substance abuse
[34]. Concerning variables predictive of QoL at study end,
the large longitudinal NEAT study found that substance
use severity at baseline did not negatively influence QoL at
follow-up [35]. We reached a similar conclusion, finding
that substance use severity at treatment admission did not
lead to a worse prognosis in terms of perceived QoL at a
later stage. On the other hand, distress in the mental health
domain was a potent negative predictor of QoL at follow-
up, as previously found in a study of outpatient partici-
pants, in which better mental health at baseline predicted
better QoL at a 3-month follow-up [22]. These findings
Table 2 Predictors of QoL at
follow-up (N = 113)
Predictor b (95 % CI)a p value
Socio-demographic variables
Gender (female) 0.00 (-0.07/0.05) 0.844
Age, years 0.00 (-0.00/0.00) 0.921
Living alone -0.08 (-0.14/-0.02) 0.007
Psychological distressc -0.08 (-0.13/-0.02) 0.007
Self-rated substance use severityb 0.00 (-0.04/0.06) 0.796
QoL-5 at baseline 0.19 (-0.05/0.43) 0.114
Follow-up variables
Mutual-help group participationd 0.00 (-0.00/0.00) 0.759
Inpatient SUD treatment during follow-up (days) 0.00 (-0.00/0.00) 0.779
Abstinence in the 30 days before follow-up 0.12 (0.06/0.18) \0.001
a Multiple linear regression with simultaneous entry of variables (the ‘‘enter’’ method); unstandardized beta
coefficient with 95 % confidence interval (CI)
b Perceived severity of the substance use, a subscale of the Survey of Readiness for AA Participation;
SYRAAP
c Symptom Check List-10, global score index
d Number of meetings in addiction-related mutual-help groups during follow-up
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imply that patients with a greater psychiatric deficit are
inherently disadvantaged when it comes to improving their
QoL.
Unexpectedly, neither inpatient SUD treatment nor
MHG support positively influenced QoL at follow-up.
However, our mean values for these data may have been
skewed by the fact that the majority of our patients had no
inpatient treatment and attended less than two MHG
meeting during the six months, as evidenced by the median
values for these variables.
Methodological considerations
The strength of the study is its use of a prospective design
that allows the examination of QoL change with time. Our
findings must, however, be interpreted in the context of
certain study limitations such as a moderate sample size.
Substance use outcomes were only taken into account for
the 30 days preceding the follow-up interview, with no
data for the first 5 months after discharge. Thus, we were
not able to evaluate whether the duration of abstinence
influenced outcome, which has been mentioned as an
important factor for any increase in QoL following treat-
ment [7, 35].
Implications
Measuring outcome following SUD treatment should not
only be based on a traditional assessment of SUD symp-
toms and SUD-related problems, but instead should
incorporate measurements of global health. This innovation
would allow us to examine whether a reduction in SUD
symptoms occurs contemporaneously with improved
physical, emotional, relational, and ontological health [10].
Thus, measurements of QoL should be used to complement
traditional outcome assessments. This would help to
emphasize and personalize the patient’s own experience
and perception of their illness and promote a greater
awareness of the value of QoL outcomes following ther-
apy. It would also help the clinical field to shift to a more
solution-focused recovery paradigm. Although our findings
indicate that abstinence from substance usage is important,
rehabilitation should be seen as a more complex process
than simply an altered pattern of substance use [10].
Conclusions
SUD populations admitted for inpatient detox treatment
suffer from poor QoL at admission. Improvements in QoL
were hampered by psychological distress and by living
without close support, but were enhanced by total
abstinence. Patients should be encouraged to obtain absti-
nence-oriented support, e.g., from formal treatment and/or
addiction-related mutual aid groups, in order to maximize
QoL improvements. Treatment providers need to address
the patient’s psychological status, implement strategies to
improve social function, and thereby promote the patient’s
interest and inclination to seek further help and support.
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